Wed, Jul 30, 2014, 1:36 PM EDT - U.S. Markets close in 2 hrs 24 mins

Recent

% | $
Click the to save as a favorite.

Celgene Corporation Message Board

  • h2145h h2145h Nov 12, 2012 10:04 AM Flag

    What CELGZ worth

    From IV board

    I put a value on them right now of $8-$9. If Abraxane is approved in pancreatic, holders get $6.93 per share; they then get 2.5% of annual sales over $1B and 5% over $2b thru 2025, Reading the tea leaves, sales could be $2b in 2015; this would amount to a payout of 62 cents per share per year for ten years. However, given what a miraculous drug this appears to be, I expect a total payout from the "stream" to be over $20, for a total payout of $27-$30 through 2025. Allowing for NPV and risk discount, I think CELGZ should trade for about $8.50 right now. After hours trading ended at $5.50.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This analysis is good but requires some clarification as the sales royalties may be much larger than what is projected here. Below are the terms--please note the 10% above $3bn which is excluded. Also note that the royalties are extended 5 years (until 2030) as long as sales stay above $1 bil. I wrote here on 10/12/12 that my discounting lead me to believe that CELGZ was undervalued. Today I feel the it is AGAIN EVEN THOUGH IT DOUBLED. Why? Because I think there is a greater than 75 % chance that the trials pipeline will add several more platforms---melanoma, etc. I believe that prior approvals will get to $1bn + and so will Panc. So were at $2 BEFORE some very large markets likely will be added, and well before the "sunset". Should we reach $4bn--possible before 2020--then we could get $275mn annually for 10 years. That's $6.39 x 10 = $63.90 per CVR. Prior I expect that $2.5bn is easy by 2017 which would payout over $1 per CVR and climb---perhaps they payout $7 per CVR upto 2020. In total we could get more than $70 PLUS the $6.93 Panc milestone in return per CVR through 2030 if Abraxane is the blockbuster I believe it is. For the record I am sceptical that they will make the April 1 milestone---but maybe if someone kicks the FDA in the #$%$---not at all likely tho--. Regardless, approval and $6.93 is NOW 99% done and any discount to $7 is a BUY as my NPV is now $11.

      Milestone 2: $300m cash upon approval of ABRAXANE by FDA for pancreatic cancer with overall survival claim in US label

      o Milestone 3: $100m cash payment upon FDA approval of ABRAXANE for pancreatic cancer if approval comes by April 1, 2013

      o Milestone 4: Potential cash royalty payments upon achievement of certain ABRAXANE and nab-pipeline products net revenue

      § 2.5% of revenue between $1bn and $2bn
      § "additional" 5% of revenue between $2bn and $3bn
      § "additional" 10% of revenue above $3bn

 
CELGZ
2.54+0.13(+5.39%)Jul 30 11:26 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.